Analyst Price Targets — BHVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 11:41 am | Douglas Tsao | H.C. Wainwright | $10.00 | $10.39 | StreetInsider | Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright |
| March 3, 2026 7:43 pm | Marc Goodman | Leerink Partners | $15.00 | $10.67 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates |
| February 5, 2026 9:18 pm | — | Goldman Sachs | $23.00 | $10.76 | TheFly | Biohaven initiated with a Buy at Goldman Sachs |
| January 21, 2026 10:09 am | — | RBC Capital | $22.00 | $12.68 | TheFly | Biohaven upgraded to Outperform from Sector Perform at RBC Capital |
| December 3, 2025 11:08 am | — | H.C. Wainwright | $11.00 | $8.83 | TheFly | Biohaven downgraded to Neutral from Buy at H.C. Wainwright |
| November 26, 2025 9:57 am | — | UBS | $11.00 | $9.24 | TheFly | Biohaven downgraded to Neutral from Buy at UBS |
| November 18, 2025 2:26 pm | — | Morgan Stanley | $26.00 | $9.45 | TheFly | Biohaven price target lowered to $26 from $54 at Morgan Stanley |
| November 5, 2025 11:09 am | Brian Skorney | Robert W. Baird | $42.00 | $13.95 | StreetInsider | Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird |
| March 20, 2025 7:39 am | — | Deutsche Bank | $60.00 | $28.18 | TheFly | Immunovant data positive for Biohaven, says Deutsche Bank |
| March 4, 2025 12:24 pm | — | Bernstein | $57.00 | $31.37 | TheFly | Biohaven price target lowered to $57 from $73 at Bernstein |
Latest News for BHVN
Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia. BHVN pivots focus to three late-stage programs: MODE/TRAP degraders [BHV-1400, BHV-1300], Kv7 activator Opakalim, and myostatin-activin inhibitor taldefgrobep alfa for obesity. Taldefgrobep alfa targets obesity with a novel MOA aiming for fat loss, muscle gain, and improved…
That pundit flagged the stock as a buy. He also expects it to more than double in price.
Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE: BHVN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 693,452 shares of the company's stock, valued at approximately $7,829,000. Aberdeen Group plc owned 0.66% of Biohaven as
SG Americas Securities LLC grew its holdings in shares of Biohaven Ltd. (NYSE: BHVN) by 291.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,518 shares of the company's stock after buying an additional 78,585 shares during the
Sarissa Capital Management added 513,184 shares in Biohaven during the fourth quarter. The quarter-end position value increased by $5.79 million as a result of the transaction.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BHVN.
U.S. House Trading
No House trades found for BHVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.